Imunon, Inc. (NASDAQ:IMNN) Short Interest Update

Imunon, Inc. (NASDAQ:IMNN) saw a significant drop in short interest in September. As of September 30th, there was short interest totalling 432,400 shares, a drop of 8.7% from the September 15th total of 473,600 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average trading volume of 2,980,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IMNN shares. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Imunon in a report on Thursday, August 15th. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Price Performance

NASDAQ:IMNN opened at $1.00 on Thursday. The firm has a market capitalization of $9.40 million, a price-to-earnings ratio of -0.50 and a beta of 2.13. The business has a 50 day simple moving average of $1.08 and a 200-day simple moving average of $1.26. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. As a group, analysts expect that Imunon will post -1.71 earnings per share for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.